Hospira Shares Fall 5.6% On Estimate Miss (HSP)

Lake Forest, Illinois-based Hospira Inc. HSP announced on Wednesday morning that it failed to meet consensus Wall Street estimates. Hospira Inc reported that its 4th quarter net income fell 37.3% to $60.6 million, or 36 cents per share, down from $96.7 million, or 58 cents per share, a year earlier. Excluding special items, the company's earnings came in at 77 cents per share. Hospira Inc reported revenue of $992 million, down 6% from $1.06 billion a year earlier. According to a survey of analysts by Thomson Reuters, the average Wall Street estimate called for earnings of 93 cents per share, on revenue of $1.04 billion. Hospira Inc. (HSP) closed the previous trading day at $55.05 per share and was down 5.6% at $51.98 per share during pre-market trading on Wednesday. Analysts covering the company's stock give it a consensus price target of $65.62 per share. Hospira Inc is the world leader in specialty generic injectable pharmaceuticals, offering one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions Read more from Benzinga's Company news.